Reata Pharmaceuticals, Inc. Contracts ApoCell, Inc. to Detect Innovative Biomarkers in a Phase II Clinical Study of RTA 402 for Diabetic Renal Disease

Published: Jun 10, 2008

HOUSTON--(BUSINESS WIRE)--ApoCell, Houston, Texas, and Reata Pharmaceuticals, Irving, Texas, announce the start of a laboratory study conducted as part of a phase II clinical trial of Reata RTA 402 for the treatment of diabetic renal disease. RTA 402 has also shown promising activity in a recent cancer phase I study of patients with advanced solid tumors.

Back to news